Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Relmada Therapeutics’ path toward bringing esmethadone (REL-1017) to patients means reading dense SEC disclosures packed with clinical trial tables and R&D spend footnotes. Searching for when management raises capital, files an 8-K after a Phase 3 readout, or sells shares through Form 4 can feel like decoding a new molecule.
Stock Titan’s AI steps in. Our engine turns every Relmada Therapeutics annual report 10-K simplified, each Relmada Therapeutics quarterly earnings report 10-Q filing, and every Relmada Therapeutics 8-K material events explained into plain-language briefs. The platform flags Relmada Therapeutics insider trading Form 4 transactions seconds after they hit EDGAR and groups them into clear charts. Prefer narrative? Understanding Relmada Therapeutics SEC documents with AI means you’ll see R&D burn, milestone payments, and cash runway highlighted automatically.
Wondering about dilution risk, royalty obligations, or executive pay? Dive into the Relmada Therapeutics proxy statement executive compensation section with pop-up tooltips, or scan Relmada Therapeutics earnings report filing analysis for quarter-over-quarter cash use. Real-time alerts on Relmada Therapeutics Form 4 insider transactions allow you to watch when key scientists exercise options. All filings—S-3 financings, 424B5 offerings, clinical 8-Ks—arrive as they’re accepted, so you never miss critical disclosures.
Need Relmada Therapeutics SEC filings explained simply? Whether you’re comparing trial costs, monitoring Relmada Therapeutics executive stock transactions Form 4, or auditing licensing commitments, our complete archive keeps every document within two clicks. Complex biotech disclosures, clarified.
On 06/30/2025, Relmada Therapeutics, Inc. (RLMD) filed a Form 4 reporting that officer Chuck Ence received an incentive stock option grant. The award, dated 06/26/2025, covers 400,000 shares of common stock at an exercise price of $0.67 per share. Vesting occurs in 16 equal quarterly installments starting 09/26/2025, with expiration on 06/26/2035. No common shares were purchased or sold; the transaction code was “A” (acquisition from the issuer) and the securities are held directly. After the grant, Ence beneficially owns 400,000 derivative securities. The filing signals continued executive retention efforts and creates potential dilution of up to 400,000 shares if the options are eventually exercised.
Relmada Therapeutics, Inc. (RLMD) – Form 4 insider filing: The company’s Chief Financial Officer, Maged Shenouda, was granted stock options for 600,000 common shares on 06/26/2025. The options carry an exercise price of $0.67 per share and will vest in 16 equal quarterly installments beginning 09/26/2025, fully vesting by 06/26/2035. Following the grant, Shenouda beneficially owns 600,000 derivative securities, reported as direct ownership. No shares were purchased or sold in the open market; this filing records an equity incentive award, aligning executive compensation with future shareholder value.
Relmada Therapeutics, Inc. (RLMD) filed a Form 4 reporting an equity award to director Charles J. Casamento. On 06/26/2025, Casamento received a stock option to purchase 100,000 RLMD common shares at an exercise price of $0.67 per share. The option will begin vesting on 09/26/2025 in 16 equal quarterly installments and will expire on 06/26/2035. Following the grant, Casamento beneficially owns 100,000 derivative securities related to RLMD, all held directly. No non-derivative share transactions were reported in this filing.
The filing signals additional potential dilution of up to 100,000 shares but also furthers alignment between the board and shareholders by tying future compensation to equity performance. No cash transactions, sales, or other insider dealings were disclosed.
Relmada Therapeutics, Inc. (RLMD) filed a Form 4 reporting an equity award to director Charles J. Casamento. On 06/26/2025, Casamento received a stock option to purchase 100,000 RLMD common shares at an exercise price of $0.67 per share. The option will begin vesting on 09/26/2025 in 16 equal quarterly installments and will expire on 06/26/2035. Following the grant, Casamento beneficially owns 100,000 derivative securities related to RLMD, all held directly. No non-derivative share transactions were reported in this filing.
The filing signals additional potential dilution of up to 100,000 shares but also furthers alignment between the board and shareholders by tying future compensation to equity performance. No cash transactions, sales, or other insider dealings were disclosed.
Relmada Therapeutics, Inc. (RLMD) filed a Form 4 disclosing a new equity award to director John Glasspool. On 06/26/2025, Glasspool received 100,000 non-qualified stock options with an exercise price of $0.67 per share. The options vest in 16 equal quarterly installments starting 09/26/2025 and expire on 06/26/2035. No common shares were bought or sold; the only reported transaction is the option grant, leaving Glasspool with 100,000 derivative securities held directly. The filing indicates normal onboarding compensation and modest potential dilution relative to RLMD’s outstanding share count (not provided in the document). Investors should view the grant as routine governance practice that aligns the new director’s incentives with long-term shareholder value without any immediate cash outlay or ownership change.
Relmada Therapeutics, Inc. (RLMD) – Form 4 filing dated 06/30/2025: Chief Operating Officer and Director Paul Edward Kelly received 400,000 stock options on 06/26/2025 at an exercise price of $0.67 per share. The options vest in 16 equal quarterly tranches beginning 09/26/2025 and will expire on 06/26/2035. Following this grant, Kelly directly holds 400,000 derivative securities; no non-derivative share purchases or sales were reported. The award provides a long-term equity incentive designed to align executive interests with shareholder value while introducing the future possibility of up to 400,000 additional common shares being issued upon exercise.
- Insider: Paul Edward Kelly – COO & Director
- Securities granted: Stock options (right to buy common stock)
- Grant size: 400,000 options
- Exercise price: $0.67
- Vesting: 16 equal quarterly installments starting 09/26/2025
- Expiration: 06/26/2035
- Ownership form: Direct
Relmada Therapeutics, Inc. (RLMD) – Form 4 filing dated 06/30/2025: Chief Operating Officer and Director Paul Edward Kelly received 400,000 stock options on 06/26/2025 at an exercise price of $0.67 per share. The options vest in 16 equal quarterly tranches beginning 09/26/2025 and will expire on 06/26/2035. Following this grant, Kelly directly holds 400,000 derivative securities; no non-derivative share purchases or sales were reported. The award provides a long-term equity incentive designed to align executive interests with shareholder value while introducing the future possibility of up to 400,000 additional common shares being issued upon exercise.
- Insider: Paul Edward Kelly – COO & Director
- Securities granted: Stock options (right to buy common stock)
- Grant size: 400,000 options
- Exercise price: $0.67
- Vesting: 16 equal quarterly installments starting 09/26/2025
- Expiration: 06/26/2035
- Ownership form: Direct
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
What is the primary focus of Relmada Therapeutics Inc?
Which therapeutic areas does Relmada address?
What is the significance of the NMDA receptor antagonist in their pipeline?
How does Relmada differentiate itself from other biotech companies?
What role does scientific expertise play at Relmada?
How does Relmada approach clinical development?
What can be said about their psilocybin program?
Are the company’s research and clinical trials transparent?
